GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Replimune Group Inc (NAS:REPL) » Definitions » ROE %
中文

Replimune Group (Replimune Group) ROE %

: -46.12% (As of Dec. 2023)
View and export this data going back to 2018. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Replimune Group's annualized net income for the quarter that ended in Dec. 2023 was $-204.48 Mil. Replimune Group's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $443.35 Mil. Therefore, Replimune Group's annualized ROE % for the quarter that ended in Dec. 2023 was -46.12%.

The historical rank and industry rank for Replimune Group's ROE % or its related term are showing as below:

REPL' s ROE % Range Over the Past 10 Years
Min: -56.17   Med: -32.73   Max: -23.7
Current: -41.15

During the past 7 years, Replimune Group's highest ROE % was -23.70%. The lowest was -56.17%. And the median was -32.73%.

REPL's ROE % is ranked better than
51.32% of 1360 companies
in the Biotechnology industry
Industry Median: -44.08 vs REPL: -41.15

Replimune Group ROE % Historical Data

The historical data trend for Replimune Group's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replimune Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE %
Get a 7-Day Free Trial -56.17 -32.73 -23.70 -25.94 -36.06

Replimune Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.42 -34.23 -37.07 -49.06 -46.12

Competitive Comparison

For the Biotechnology subindustry, Replimune Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Replimune Group ROE % Distribution

For the Biotechnology industry and Healthcare sector, Replimune Group's ROE % distribution charts can be found below:

* The bar in red indicates where Replimune Group's ROE % falls into.



Replimune Group ROE % Calculation

Replimune Group's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=-174.284/( (411.229+555.292)/ 2 )
=-174.284/483.2605
=-36.06 %

Replimune Group's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-204.48/( (465.172+421.537)/ 2 )
=-204.48/443.3545
=-46.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Replimune Group  (NAS:REPL) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-204.48/443.3545
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-204.48 / 0)*(0 / 547.664)*(547.664 / 443.3545)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.2353
=ROA %*Equity Multiplier
=N/A %*1.2353
=-46.12 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-204.48/443.3545
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-204.48 / -202.588) * (-202.588 / -224.5) * (-224.5 / 0) * (0 / 547.664) * (547.664 / 443.3545)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0093 * 0.9024 * N/A % * 0 * 1.2353
=-46.12 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Replimune Group ROE % Related Terms

Thank you for viewing the detailed overview of Replimune Group's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Replimune Group (Replimune Group) Business Description

Traded in Other Exchanges
Address
500 Unicorn Park Drive, Suite 303, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Executives
Christopher Sarchi officer: Chief Commercial Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Konstantinos Xynos officer: Chief Medical Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Emily Luisa Hill officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pamela Esposito officer: Chief Business Officer C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Sushil Patel officer: Chief Commercial Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Tanya Lewis director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Veleka Peeples-dyer director C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Andrew Schwendenman officer: Chief Accounting Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Philip Astley-sparke director, 10 percent owner, officer: Executive Chairman C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Robert Coffin director, 10 percent owner, officer: President and C.E.O. C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Love Colin 10 percent owner, officer: Chief Operating Officer C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 10801
Jean M. Franchi officer: Chief Financial Officer C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Omega Fund Iv Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Christy J. Oliger director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Jason P Rhodes director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139